Japanese study on current Anticoagulation therapies for Patients with nonvalvular Atrial Fibrillation.

Japanese study on current Anticoagulation therapies for Patients with nonvalvular Atrial Fibrillation. - Japanese study on current Anticoagulation therapies for Patients with nonvalvular Atrial Fibrillation. (JAPAF)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009644

Enrollment

5000

Registered

2012-12-27

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonvalvularAtrial Fibrillation patients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with nonvalvular atrial fibrillation who have been treated with antithrombotic medicines (other than dabigatran etexilate) in order to prevent from ischemic stroke and systemic embolism. The post-marketing surveillance for dabigatran etexilate is separately conducted by its manufacturer.We will apply the result of the surveillance to our study, therefore patients on dabigatran etexilate treatment won't be included.

Exclusion criteria

Exclusion criteria: There are no exclusion criteria for this study.

Design outcomes

Primary

Measure	Time frame
Associations of various clinical factors with selection of antithrombotic drugs	—

Countries

Japan

Contacts

Public ContactKoji Harada

Kyoto University Graduate School of Medicine Department of Health and Environmental Sciences

AFAntithrombotic@umin.ac.jp075-753-4456

Outcome results